Icecure Medical Ltd
TASE:ICCM
Intrinsic Value
IceCure Medical Ltd. is a commercial stage medical device company, which engages in the research and development, design, manufacture, and marketing of cryoablation systems and technologies based on l... [ Read More ]
The intrinsic value of one ICCM stock under the Base Case scenario is 77.65 ILS. Compared to the current market price of 425.9 ILS, Icecure Medical Ltd is Overvalued by 82%.
Valuation Backtest
Icecure Medical Ltd
Run backtest to discover the historical profit from buying and selling ICCM stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Icecure Medical Ltd
| Current Assets | 24.7m |
| Cash & Short-Term Investments | 20.5m |
| Receivables | 143k |
| Other Current Assets | 4.1m |
| Non-Current Assets | 2.2m |
| PP&E | 2.1m |
| Other Non-Current Assets | 34k |
| Current Liabilities | 4.5m |
| Accounts Payable | 685k |
| Accrued Liabilities | 164k |
| Other Current Liabilities | 3.6m |
| Non-Current Liabilities | 376k |
| Other Non-Current Liabilities | 376k |
Earnings Waterfall
Icecure Medical Ltd
|
Revenue
|
3m
USD
|
|
Cost of Revenue
|
-1.7m
USD
|
|
Gross Profit
|
1.3m
USD
|
|
Operating Expenses
|
-17.6m
USD
|
|
Operating Income
|
-16.3m
USD
|
|
Other Expenses
|
-28k
USD
|
|
Net Income
|
-16.3m
USD
|
Free Cash Flow Analysis
Icecure Medical Ltd
ICCM Profitability Score
Profitability Due Diligence
Icecure Medical Ltd's profitability score is 25/100. The higher the profitability score, the more profitable the company is.
Score
Icecure Medical Ltd's profitability score is 25/100. The higher the profitability score, the more profitable the company is.
ICCM Solvency Score
Solvency Due Diligence
Icecure Medical Ltd's solvency score is 81/100. The higher the solvency score, the more solvent the company is.
Score
Icecure Medical Ltd's solvency score is 81/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
ICCM Price Targets Summary
Icecure Medical Ltd
Shareholder Return
ICCM Price
Icecure Medical Ltd
| Average Annual Return | 32.9% |
| Standard Deviation of Annual Returns | 64.21% |
| Max Drawdown | -92% |
| Market Capitalization | 193.3m ILS |
| Shares Outstanding | 453 839 |
| Percentage of Shares Shorted |
N/A
|
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
IceCure Medical Ltd. is a commercial stage medical device company, which engages in the research and development, design, manufacture, and marketing of cryoablation systems and technologies based on liquid nitrogen for the treatment of tumors. The firm develops and markets minimally invasive cryoablation therapies for women’s health and general oncology market. Icecure Medical Ltd’s proprietary IceSense3 and ProSense systems provide minimally invasive, in-office definitive treatment for symptomatic tumors in various organs. The procedure is done under ultrasound or Computed Tomography (CT) imaging to guide a small probe (thin hollow needle) into the tumor. The system then uses extremely cold temperatures to destroy (ablate) the targeted tumor in situ. Icecure Medical Ltd supports investigator-initiated studies at various academic institutions around the globe, including Kameda and Saint Johns.
Officers
The intrinsic value of one ICCM stock under the Base Case scenario is 77.65 ILS.
Compared to the current market price of 425.9 ILS, Icecure Medical Ltd is Overvalued by 82%.
You don't have any saved screeners yet
